The Top 5 Biosimilars Articles for the Week of August 12

The Center for Biosimilars® recaps the top stories for the week of August 12, 2019.


Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 12, 2019.

Number 5: Being presented with positively framed information on biosimilars is linked with greater willingness to accept a switch, says a recent study.

Number 4: New data from a phase 3 study in patients with rheumatoid arthritis show that Fresenius Kabi’s biosimilar adalimumab has similar safety to Humira.

Number 3: A retrospective analysis of prescription claims shows the importance of an oncology specialty pharmacy team in ensuring access to financial assistance.

Number 2: Authors of a new paper say it’s time to replace the totality of the evidence approach to biosimilars with a new paradigm.

Number 1: A judge ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi.

Finally, last week, our e-newsletter asked whether you think that Celltrion’s proposed subcutaneous infliximab biosimilar could compete with brand-name adalimumab.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumschild, PharmD
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.